Shelley Miyamoto
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Transplantation | 34 | 2023 | 689 | 3.920 |
Why?
| Heart Defects, Congenital | 14 | 2023 | 746 | 2.750 |
Why?
| Heart Ventricles | 15 | 2022 | 763 | 2.500 |
Why?
| Cardiomyopathy, Dilated | 13 | 2021 | 359 | 2.480 |
Why?
| MicroRNAs | 8 | 2023 | 660 | 1.890 |
Why?
| Heart Failure | 16 | 2023 | 2154 | 1.880 |
Why?
| Circulating MicroRNA | 3 | 2023 | 24 | 1.690 |
Why?
| Cardiomyopathies | 7 | 2023 | 314 | 1.690 |
Why?
| Myocardium | 8 | 2021 | 992 | 1.520 |
Why?
| Hypoplastic Left Heart Syndrome | 6 | 2017 | 113 | 1.430 |
Why?
| Milrinone | 2 | 2021 | 27 | 1.270 |
Why?
| Ventricular Remodeling | 4 | 2021 | 238 | 1.240 |
Why?
| Myocytes, Cardiac | 7 | 2021 | 487 | 1.240 |
Why?
| Cardiomyopathy, Hypertrophic | 3 | 2023 | 124 | 1.030 |
Why?
| Ventricular Function, Right | 2 | 2018 | 272 | 1.030 |
Why?
| Heart Diseases | 5 | 2023 | 364 | 0.970 |
Why?
| Child | 58 | 2023 | 20014 | 0.940 |
Why?
| Graft Rejection | 8 | 2021 | 555 | 0.910 |
Why?
| Ventricular Function, Left | 5 | 2018 | 511 | 0.770 |
Why?
| Infant | 32 | 2022 | 8625 | 0.760 |
Why?
| Graft Survival | 7 | 2023 | 510 | 0.750 |
Why?
| Child, Preschool | 36 | 2021 | 9938 | 0.690 |
Why?
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 77 | 0.670 |
Why?
| Receptors, Adrenergic, beta | 3 | 2016 | 154 | 0.660 |
Why?
| Phosphodiesterase 3 Inhibitors | 2 | 2016 | 13 | 0.650 |
Why?
| Fever | 1 | 2020 | 294 | 0.630 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 23 | 0.630 |
Why?
| Down-Regulation | 3 | 2021 | 652 | 0.610 |
Why?
| Steroids | 2 | 2015 | 158 | 0.570 |
Why?
| Hemodynamics | 6 | 2015 | 1093 | 0.550 |
Why?
| Hypertrophy, Right Ventricular | 1 | 2017 | 147 | 0.550 |
Why?
| Humans | 80 | 2023 | 125132 | 0.520 |
Why?
| Female | 60 | 2023 | 64890 | 0.520 |
Why?
| Male | 55 | 2023 | 60793 | 0.520 |
Why?
| Fontan Procedure | 4 | 2023 | 162 | 0.520 |
Why?
| Histone Deacetylases | 1 | 2017 | 204 | 0.510 |
Why?
| Echocardiography | 6 | 2021 | 609 | 0.470 |
Why?
| Biomarkers | 9 | 2021 | 3736 | 0.460 |
Why?
| Case-Control Studies | 8 | 2021 | 3326 | 0.440 |
Why?
| Adaptation, Physiological | 2 | 2017 | 517 | 0.420 |
Why?
| Cardiovascular Diseases | 2 | 2022 | 1904 | 0.410 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2012 | 44 | 0.410 |
Why?
| Waiting Lists | 2 | 2013 | 231 | 0.410 |
Why?
| Animals, Newborn | 5 | 2021 | 830 | 0.390 |
Why?
| Recovery of Function | 2 | 2015 | 620 | 0.390 |
Why?
| Phosphoric Diester Hydrolases | 3 | 2016 | 45 | 0.380 |
Why?
| Calcium-Binding Proteins | 3 | 2021 | 221 | 0.380 |
Why?
| Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 29 | 0.380 |
Why?
| Dexmedetomidine | 3 | 2017 | 52 | 0.370 |
Why?
| Gene Expression Regulation | 3 | 2016 | 2492 | 0.370 |
Why?
| Adolescent | 32 | 2023 | 19411 | 0.360 |
Why?
| Phenotype | 4 | 2023 | 3153 | 0.350 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2010 | 259 | 0.340 |
Why?
| Age Factors | 9 | 2018 | 3152 | 0.330 |
Why?
| Primary Graft Dysfunction | 1 | 2009 | 33 | 0.330 |
Why?
| Cardiolipins | 3 | 2021 | 73 | 0.330 |
Why?
| Prospective Studies | 11 | 2021 | 6818 | 0.320 |
Why?
| Rats, Sprague-Dawley | 5 | 2021 | 2512 | 0.320 |
Why?
| Adenosine Monophosphate | 2 | 2021 | 52 | 0.320 |
Why?
| Reoviridae Infections | 1 | 2009 | 55 | 0.310 |
Why?
| Granuloma, Plasma Cell | 1 | 2008 | 11 | 0.310 |
Why?
| Myocarditis | 1 | 2009 | 99 | 0.300 |
Why?
| Signal Transduction | 3 | 2017 | 4809 | 0.300 |
Why?
| Retrospective Studies | 21 | 2021 | 13708 | 0.290 |
Why?
| Cardiac Catheterization | 4 | 2017 | 594 | 0.280 |
Why?
| Kidney Transplantation | 2 | 2023 | 593 | 0.280 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 334 | 0.280 |
Why?
| Ventricular Outflow Obstruction | 2 | 2022 | 41 | 0.280 |
Why?
| Databases, Factual | 5 | 2016 | 1298 | 0.280 |
Why?
| Phosphorylation | 4 | 2021 | 1694 | 0.270 |
Why?
| Immunosuppressive Agents | 4 | 2023 | 693 | 0.270 |
Why?
| Calcium | 3 | 2021 | 1211 | 0.260 |
Why?
| Infant, Newborn | 10 | 2021 | 5456 | 0.260 |
Why?
| Coronary Artery Disease | 3 | 2018 | 721 | 0.250 |
Why?
| Fibrosis | 2 | 2017 | 497 | 0.240 |
Why?
| Adenylyl Cyclases | 2 | 2016 | 142 | 0.240 |
Why?
| Treatment Outcome | 14 | 2021 | 9790 | 0.240 |
Why?
| Coronary Vessels | 2 | 2017 | 256 | 0.240 |
Why?
| Heart-Assist Devices | 4 | 2019 | 499 | 0.230 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2023 | 10 | 0.220 |
Why?
| Heart | 3 | 2022 | 668 | 0.210 |
Why?
| Pulmonary Artery | 1 | 2009 | 1110 | 0.210 |
Why?
| Sarcomeres | 1 | 2023 | 93 | 0.210 |
Why?
| Data Accuracy | 1 | 2022 | 66 | 0.200 |
Why?
| Fibroma | 1 | 2022 | 20 | 0.200 |
Why?
| Cyclic AMP | 2 | 2014 | 264 | 0.200 |
Why?
| Transcriptome | 2 | 2021 | 801 | 0.200 |
Why?
| Heart Neoplasms | 1 | 2022 | 53 | 0.200 |
Why?
| Barth Syndrome | 1 | 2021 | 9 | 0.200 |
Why?
| Electron Transport Complex I | 1 | 2021 | 36 | 0.190 |
Why?
| Focal Adhesions | 1 | 2021 | 44 | 0.190 |
Why?
| Longevity | 1 | 2022 | 156 | 0.190 |
Why?
| Cardiopulmonary Bypass | 3 | 2022 | 207 | 0.190 |
Why?
| Fetofetal Transfusion | 1 | 2021 | 23 | 0.190 |
Why?
| Amniotic Fluid | 1 | 2021 | 69 | 0.190 |
Why?
| Cytokines | 1 | 2009 | 1927 | 0.190 |
Why?
| Heart Rate | 3 | 2023 | 758 | 0.180 |
Why?
| Calcium Channel Agonists | 1 | 2020 | 10 | 0.180 |
Why?
| Probenecid | 1 | 2020 | 10 | 0.180 |
Why?
| Cardiac Output, Low | 1 | 2021 | 76 | 0.180 |
Why?
| Cells, Cultured | 4 | 2019 | 4159 | 0.180 |
Why?
| Serum | 2 | 2018 | 66 | 0.180 |
Why?
| Isoproterenol | 2 | 2018 | 137 | 0.180 |
Why?
| Cardiotonic Agents | 1 | 2021 | 133 | 0.180 |
Why?
| Young Adult | 12 | 2023 | 11385 | 0.170 |
Why?
| Hypertension, Pulmonary | 3 | 2017 | 1880 | 0.170 |
Why?
| ROC Curve | 3 | 2017 | 501 | 0.170 |
Why?
| Apoptosis | 1 | 2009 | 2553 | 0.170 |
Why?
| Immunoglobulins, Intravenous | 1 | 2020 | 129 | 0.170 |
Why?
| Atrial Function, Right | 1 | 2019 | 15 | 0.170 |
Why?
| Tissue Donors | 3 | 2016 | 352 | 0.160 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 38 | 0.160 |
Why?
| Troponin I | 1 | 2019 | 84 | 0.160 |
Why?
| Fatty Acids | 1 | 2021 | 414 | 0.160 |
Why?
| Phosphodiesterase Inhibitors | 2 | 2016 | 90 | 0.160 |
Why?
| Mitochondria, Heart | 2 | 2020 | 85 | 0.160 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 243 | 0.160 |
Why?
| Phosphodiesterase 5 Inhibitors | 1 | 2018 | 39 | 0.160 |
Why?
| Heart Atria | 1 | 2019 | 122 | 0.150 |
Why?
| Kidney Failure, Chronic | 1 | 2023 | 523 | 0.150 |
Why?
| Ventricular Dysfunction, Left | 2 | 2013 | 402 | 0.150 |
Why?
| Surgical Wound Dehiscence | 1 | 2017 | 24 | 0.150 |
Why?
| Extracellular Matrix | 1 | 2021 | 462 | 0.150 |
Why?
| Protein Kinase C beta | 1 | 2017 | 26 | 0.150 |
Why?
| Receptors, Adrenergic, alpha-2 | 1 | 2017 | 17 | 0.140 |
Why?
| Patient Transfer | 1 | 2019 | 160 | 0.140 |
Why?
| Time Factors | 6 | 2018 | 6780 | 0.140 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 16 | 0.140 |
Why?
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.140 |
Why?
| Animals | 10 | 2021 | 34345 | 0.140 |
Why?
| Survival Analysis | 4 | 2021 | 1341 | 0.140 |
Why?
| Galectin 3 | 1 | 2016 | 21 | 0.140 |
Why?
| Kaplan-Meier Estimate | 3 | 2015 | 879 | 0.140 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2016 | 59 | 0.140 |
Why?
| Drug Administration Schedule | 2 | 2017 | 760 | 0.140 |
Why?
| Vectorcardiography | 1 | 2016 | 5 | 0.140 |
Why?
| Specimen Handling | 1 | 2018 | 171 | 0.140 |
Why?
| Transition to Adult Care | 1 | 2017 | 66 | 0.140 |
Why?
| Sirolimus | 1 | 2017 | 199 | 0.140 |
Why?
| Perioperative Care | 1 | 2017 | 137 | 0.140 |
Why?
| Genetic Markers | 1 | 2017 | 368 | 0.140 |
Why?
| Research Design | 1 | 2022 | 1035 | 0.140 |
Why?
| Renal Insufficiency, Chronic | 1 | 2023 | 612 | 0.130 |
Why?
| Self Care | 1 | 2019 | 370 | 0.130 |
Why?
| Adult | 12 | 2023 | 33168 | 0.130 |
Why?
| Isoenzymes | 1 | 2017 | 311 | 0.130 |
Why?
| Death, Sudden, Cardiac | 1 | 2018 | 218 | 0.130 |
Why?
| Electrocardiography | 3 | 2015 | 637 | 0.130 |
Why?
| Mutation | 3 | 2023 | 3520 | 0.130 |
Why?
| Plasma | 1 | 2018 | 224 | 0.130 |
Why?
| Vascular Resistance | 1 | 2017 | 372 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 299 | 0.130 |
Why?
| Exosomes | 1 | 2017 | 92 | 0.130 |
Why?
| Vasoconstriction | 1 | 2017 | 217 | 0.130 |
Why?
| Arrhythmias, Cardiac | 1 | 2018 | 313 | 0.130 |
Why?
| Risk Factors | 9 | 2018 | 9549 | 0.130 |
Why?
| Statistics as Topic | 1 | 2016 | 319 | 0.130 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2018 | 537 | 0.120 |
Why?
| Up-Regulation | 1 | 2018 | 895 | 0.120 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2012 | 83 | 0.120 |
Why?
| Surgical Wound Infection | 1 | 2017 | 263 | 0.120 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2015 | 68 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 169 | 0.120 |
Why?
| Exercise Test | 3 | 2023 | 585 | 0.120 |
Why?
| Hypnotics and Sedatives | 1 | 2015 | 149 | 0.120 |
Why?
| Ketamine | 1 | 2015 | 106 | 0.120 |
Why?
| Stroke Volume | 2 | 2016 | 570 | 0.120 |
Why?
| Rats | 4 | 2021 | 5517 | 0.120 |
Why?
| Tachycardia, Ventricular | 1 | 2016 | 172 | 0.120 |
Why?
| Hypoalbuminemia | 1 | 2014 | 27 | 0.120 |
Why?
| Gene Expression Profiling | 2 | 2021 | 1642 | 0.110 |
Why?
| Prognosis | 4 | 2015 | 3616 | 0.110 |
Why?
| Organ Transplantation | 1 | 2016 | 170 | 0.110 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 9 | 0.110 |
Why?
| Propensity Score | 1 | 2015 | 257 | 0.110 |
Why?
| Growth Disorders | 1 | 2014 | 87 | 0.110 |
Why?
| Anthracyclines | 1 | 2013 | 42 | 0.110 |
Why?
| Patient Compliance | 1 | 2017 | 571 | 0.110 |
Why?
| Fetal Heart | 1 | 2013 | 37 | 0.110 |
Why?
| Coronary Angiography | 1 | 2016 | 353 | 0.110 |
Why?
| Tissue and Organ Procurement | 1 | 2016 | 258 | 0.110 |
Why?
| Vascular Diseases | 1 | 2016 | 251 | 0.110 |
Why?
| Cerebral Arterial Diseases | 1 | 2012 | 43 | 0.100 |
Why?
| Patient Education as Topic | 1 | 2017 | 734 | 0.100 |
Why?
| Connexin 43 | 1 | 2012 | 24 | 0.100 |
Why?
| Myosin Heavy Chains | 1 | 2014 | 193 | 0.100 |
Why?
| Interleukin-1 | 1 | 2016 | 984 | 0.100 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 159 | 0.100 |
Why?
| Heart Arrest | 1 | 2015 | 312 | 0.100 |
Why?
| Natriuretic Peptide, Brain | 1 | 2012 | 108 | 0.100 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 175 | 0.100 |
Why?
| Altitude | 2 | 2021 | 461 | 0.090 |
Why?
| Follow-Up Studies | 6 | 2021 | 4824 | 0.090 |
Why?
| American Heart Association | 2 | 2023 | 314 | 0.090 |
Why?
| Ventricular Dysfunction, Right | 1 | 2014 | 242 | 0.090 |
Why?
| Incidence | 2 | 2015 | 2578 | 0.090 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 61 | 0.090 |
Why?
| Pulmonary Embolism | 1 | 2012 | 183 | 0.090 |
Why?
| Lymphoproliferative Disorders | 1 | 2010 | 46 | 0.090 |
Why?
| Fibrinolytic Agents | 1 | 2012 | 256 | 0.090 |
Why?
| Mycoses | 1 | 2010 | 71 | 0.090 |
Why?
| Blood Coagulation Disorders | 1 | 2012 | 220 | 0.090 |
Why?
| Disease Management | 1 | 2014 | 599 | 0.090 |
Why?
| RNA | 1 | 2016 | 875 | 0.090 |
Why?
| Patient Selection | 1 | 2014 | 725 | 0.090 |
Why?
| Transplantation Conditioning | 1 | 2010 | 159 | 0.080 |
Why?
| Oxygen Consumption | 2 | 2023 | 620 | 0.080 |
Why?
| Transcription, Genetic | 1 | 2015 | 1376 | 0.080 |
Why?
| Thrombophilia | 1 | 2009 | 70 | 0.080 |
Why?
| Transplantation, Homologous | 3 | 2021 | 434 | 0.080 |
Why?
| Colorado | 6 | 2017 | 4471 | 0.080 |
Why?
| Air Ambulances | 1 | 2010 | 53 | 0.080 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 1248 | 0.080 |
Why?
| Cohort Studies | 6 | 2015 | 5348 | 0.080 |
Why?
| Cardiac Surgical Procedures | 2 | 2017 | 490 | 0.080 |
Why?
| Travel | 1 | 2010 | 131 | 0.080 |
Why?
| Mitral Valve Stenosis | 1 | 2008 | 22 | 0.080 |
Why?
| Cytomegalovirus Infections | 1 | 2010 | 194 | 0.080 |
Why?
| Angioplasty, Balloon | 1 | 2009 | 93 | 0.080 |
Why?
| Registries | 2 | 2014 | 2050 | 0.080 |
Why?
| RNA, Transfer, Glu | 1 | 2007 | 5 | 0.070 |
Why?
| Reoperation | 3 | 2021 | 571 | 0.070 |
Why?
| United States | 7 | 2022 | 13613 | 0.070 |
Why?
| RNA, Messenger | 3 | 2021 | 2753 | 0.070 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1530 | 0.070 |
Why?
| Oxidation-Reduction | 2 | 2021 | 943 | 0.070 |
Why?
| Mitochondrial Diseases | 1 | 2007 | 80 | 0.070 |
Why?
| Pregnancy | 2 | 2021 | 5922 | 0.070 |
Why?
| Brain Ischemia | 1 | 2009 | 310 | 0.070 |
Why?
| Stem Cells | 1 | 2010 | 570 | 0.070 |
Why?
| Myocardial Contraction | 2 | 2019 | 339 | 0.060 |
Why?
| Stents | 1 | 2009 | 504 | 0.060 |
Why?
| Stroke | 1 | 2012 | 1098 | 0.060 |
Why?
| Pilot Projects | 2 | 2019 | 1530 | 0.060 |
Why?
| Middle Aged | 4 | 2016 | 29112 | 0.060 |
Why?
| Polymerase Chain Reaction | 2 | 2017 | 1042 | 0.050 |
Why?
| Risk | 2 | 2019 | 896 | 0.050 |
Why?
| Palliative Care | 1 | 2009 | 664 | 0.050 |
Why?
| Everolimus | 1 | 2023 | 64 | 0.050 |
Why?
| Blotting, Western | 2 | 2016 | 1233 | 0.050 |
Why?
| Mycophenolic Acid | 1 | 2023 | 81 | 0.050 |
Why?
| Severity of Illness Index | 3 | 2021 | 2848 | 0.050 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 785 | 0.050 |
Why?
| Tacrolimus | 1 | 2023 | 153 | 0.050 |
Why?
| Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| Ribonucleases | 1 | 2021 | 55 | 0.050 |
Why?
| Acyltransferases | 1 | 2021 | 54 | 0.050 |
Why?
| Light Coagulation | 1 | 2021 | 7 | 0.050 |
Why?
| Exercise Tolerance | 1 | 2023 | 245 | 0.050 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 83 | 0.050 |
Why?
| Serum Response Factor | 1 | 2021 | 30 | 0.050 |
Why?
| Fetoscopy | 1 | 2021 | 29 | 0.050 |
Why?
| Sensitivity and Specificity | 2 | 2016 | 1885 | 0.050 |
Why?
| Microscopy, Atomic Force | 1 | 2021 | 119 | 0.050 |
Why?
| Genotype | 2 | 2017 | 1960 | 0.050 |
Why?
| Drainage | 1 | 2021 | 160 | 0.040 |
Why?
| Gene Expression | 2 | 2017 | 1528 | 0.040 |
Why?
| TRPV Cation Channels | 1 | 2020 | 35 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2023 | 709 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2014 | 1561 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2023 | 1006 | 0.040 |
Why?
| Postoperative Complications | 3 | 2021 | 2325 | 0.040 |
Why?
| Ultrasonography, Prenatal | 1 | 2021 | 242 | 0.040 |
Why?
| Cluster Analysis | 1 | 2021 | 497 | 0.040 |
Why?
| Recurrence | 2 | 2012 | 1011 | 0.040 |
Why?
| Resource Allocation | 1 | 2019 | 41 | 0.040 |
Why?
| Neoplasms | 1 | 2013 | 2340 | 0.040 |
Why?
| Exercise Therapy | 1 | 2023 | 387 | 0.040 |
Why?
| Inflammation | 1 | 2009 | 2612 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 410 | 0.040 |
Why?
| Ventricular Function | 1 | 2019 | 61 | 0.040 |
Why?
| HEK293 Cells | 1 | 2021 | 654 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 423 | 0.040 |
Why?
| Risk Assessment | 3 | 2016 | 3274 | 0.040 |
Why?
| DNA, Mitochondrial | 1 | 2020 | 191 | 0.040 |
Why?
| Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2017 | 2135 | 0.040 |
Why?
| Treatment Failure | 2 | 2010 | 348 | 0.040 |
Why?
| Guinea Pigs | 1 | 2018 | 159 | 0.040 |
Why?
| Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 61 | 0.040 |
Why?
| Administration, Oral | 1 | 2020 | 785 | 0.040 |
Why?
| Freezing | 1 | 2018 | 86 | 0.040 |
Why?
| Anti-Arrhythmia Agents | 1 | 2018 | 131 | 0.040 |
Why?
| Adenoidectomy | 1 | 2017 | 66 | 0.040 |
Why?
| Cell Size | 1 | 2017 | 87 | 0.030 |
Why?
| Atrial Natriuretic Factor | 1 | 2016 | 60 | 0.030 |
Why?
| Sampling Studies | 1 | 2016 | 97 | 0.030 |
Why?
| Homeostasis | 1 | 2020 | 605 | 0.030 |
Why?
| Observer Variation | 1 | 2017 | 330 | 0.030 |
Why?
| Renin-Angiotensin System | 1 | 2017 | 87 | 0.030 |
Why?
| Brain Death | 1 | 2016 | 32 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2018 | 3823 | 0.030 |
Why?
| Tonsillectomy | 1 | 2017 | 84 | 0.030 |
Why?
| Kidney | 1 | 2023 | 1379 | 0.030 |
Why?
| Feasibility Studies | 1 | 2019 | 806 | 0.030 |
Why?
| Mitochondria | 1 | 2021 | 823 | 0.030 |
Why?
| Sympathetic Nervous System | 1 | 2017 | 174 | 0.030 |
Why?
| Autopsy | 1 | 2016 | 93 | 0.030 |
Why?
| Stem Cell Transplantation | 1 | 2017 | 155 | 0.030 |
Why?
| Hot Temperature | 1 | 2018 | 345 | 0.030 |
Why?
| Diastole | 1 | 2016 | 146 | 0.030 |
Why?
| Systole | 1 | 2016 | 190 | 0.030 |
Why?
| Self-Management | 1 | 2017 | 139 | 0.030 |
Why?
| Italy | 1 | 2015 | 94 | 0.030 |
Why?
| Cell Line | 1 | 2021 | 2806 | 0.030 |
Why?
| Cardiac Output | 1 | 2015 | 154 | 0.030 |
Why?
| Carrier Proteins | 1 | 2019 | 743 | 0.030 |
Why?
| Markov Chains | 1 | 2015 | 122 | 0.030 |
Why?
| Action Potentials | 1 | 2018 | 434 | 0.030 |
Why?
| DNA, Complementary | 1 | 2015 | 276 | 0.030 |
Why?
| Reference Values | 1 | 2016 | 818 | 0.030 |
Why?
| Arterial Pressure | 1 | 2015 | 108 | 0.030 |
Why?
| Orthopedic Procedures | 1 | 2017 | 223 | 0.030 |
Why?
| Public Health | 1 | 2019 | 493 | 0.030 |
Why?
| Exons | 1 | 2015 | 316 | 0.030 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2017 | 188 | 0.030 |
Why?
| Cardiovascular Surgical Procedures | 1 | 2014 | 38 | 0.030 |
Why?
| Analgesics | 1 | 2015 | 172 | 0.030 |
Why?
| Linear Models | 1 | 2016 | 870 | 0.030 |
Why?
| Drug Therapy | 1 | 2014 | 78 | 0.030 |
Why?
| Pandemics | 1 | 2022 | 1434 | 0.030 |
Why?
| Self Report | 1 | 2017 | 750 | 0.030 |
Why?
| Analysis of Variance | 1 | 2016 | 1366 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 1050 | 0.030 |
Why?
| Program Evaluation | 1 | 2017 | 896 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2013 | 118 | 0.030 |
Why?
| Mice | 3 | 2015 | 15984 | 0.030 |
Why?
| Exercise | 1 | 2023 | 1779 | 0.030 |
Why?
| Transplant Recipients | 1 | 2014 | 150 | 0.030 |
Why?
| Mitochondrial Proteins | 1 | 2014 | 233 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 837 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 2013 | 269 | 0.020 |
Why?
| Heart Function Tests | 1 | 2012 | 66 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2016 | 1431 | 0.020 |
Why?
| Pediatrics | 1 | 2019 | 1046 | 0.020 |
Why?
| Nutritional Status | 1 | 2014 | 304 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2016 | 1992 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1191 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2017 | 2669 | 0.020 |
Why?
| Mice, Inbred C3H | 1 | 2010 | 259 | 0.020 |
Why?
| Mass Screening | 1 | 2017 | 1119 | 0.020 |
Why?
| France | 1 | 2010 | 36 | 0.020 |
Why?
| Diagnostic Imaging | 1 | 2012 | 311 | 0.020 |
Why?
| Factor VIII | 1 | 2009 | 56 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2010 | 276 | 0.020 |
Why?
| Shock, Cardiogenic | 1 | 2010 | 63 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2010 | 260 | 0.020 |
Why?
| Body Weight | 1 | 2014 | 960 | 0.020 |
Why?
| Survival Rate | 1 | 2014 | 1799 | 0.020 |
Why?
| Adaptive Immunity | 1 | 2010 | 163 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2010 | 558 | 0.020 |
Why?
| Internationality | 1 | 2010 | 162 | 0.020 |
Why?
| Tricuspid Atresia | 1 | 2008 | 7 | 0.020 |
Why?
| Venae Cavae | 1 | 2008 | 10 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2013 | 2026 | 0.020 |
Why?
| Vena Cava, Superior | 1 | 2008 | 22 | 0.020 |
Why?
| Device Removal | 1 | 2009 | 116 | 0.020 |
Why?
| Biopsy | 1 | 2012 | 1093 | 0.020 |
Why?
| Anastomosis, Surgical | 1 | 2008 | 146 | 0.020 |
Why?
| Age of Onset | 1 | 2009 | 484 | 0.020 |
Why?
| Anticoagulants | 1 | 2012 | 587 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2010 | 1233 | 0.020 |
Why?
| Probability | 1 | 2008 | 318 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2015 | 3047 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2009 | 381 | 0.020 |
Why?
| Fatal Outcome | 1 | 2007 | 299 | 0.020 |
Why?
| Pulmonary Circulation | 1 | 2008 | 456 | 0.020 |
Why?
| Aged | 2 | 2014 | 20859 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2017 | 5062 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2008 | 1200 | 0.020 |
Why?
| Length of Stay | 1 | 2008 | 1077 | 0.010 |
Why?
| T-Lymphocytes | 1 | 2010 | 1793 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|